These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 2077433)
1. Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls. Catapano F; Monteleone P; Maj M; Kemali D Neuropsychobiology; 1990; 23(2):53-6. PubMed ID: 2077433 [TBL] [Abstract][Full Text] [Related]
2. Abnormal dexamethasone suppression test in primary obsessive-compulsive patients: a confirmatory report. Cottraux JA; Bouvard M; Claustrat B; Juenet C Psychiatry Res; 1984 Oct; 13(2):157-65. PubMed ID: 6596583 [TBL] [Abstract][Full Text] [Related]
3. The dexamethasone suppression test in patients with primary obsessive-compulsive disorder. Insel TR; Kalin NH; Guttmacher LB; Cohen RM; Murphy DL Psychiatry Res; 1982 Apr; 6(2):153-60. PubMed ID: 6953457 [TBL] [Abstract][Full Text] [Related]
6. Dexamethasone suppression tests in patients with obsessive-compulsive disorder. Lieberman JA; Kane JM; Sarantakos S; Cole K; Howard A; Borenstein M; Novacenko H; Puig-Antich J Am J Psychiatry; 1985 Jun; 142(6):747-51. PubMed ID: 4003598 [TBL] [Abstract][Full Text] [Related]
7. Neopterin levels and dexamethasone suppression test in obsessive-compulsive disorder. Kuloğlu M; Atmaca M; Onal S; Geçici O; Bulut V; Tezcan E Psychiatry Res; 2007 Jun; 151(3):265-70. PubMed ID: 17467061 [TBL] [Abstract][Full Text] [Related]
13. Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. Monteleone P; Catapano F; Tortorella A; Maj M Neuropsychobiology; 1997; 36(1):8-12. PubMed ID: 9211437 [TBL] [Abstract][Full Text] [Related]
15. The desipramine-induced growth hormone response and the dexamethasone suppression test in obsessive-compulsive disorder. Lucey JV; Barry S; Webb MG; Dinan TG Acta Psychiatr Scand; 1992 Nov; 86(5):367-70. PubMed ID: 1336635 [TBL] [Abstract][Full Text] [Related]
16. Increased nocturnal secretion of ACTH and cortisol in obsessive compulsive disorder. Kluge M; Schüssler P; Künzel HE; Dresler M; Yassouridis A; Steiger A J Psychiatr Res; 2007 Dec; 41(11):928-33. PubMed ID: 17049559 [TBL] [Abstract][Full Text] [Related]
17. Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview. du Toit PL; van Kradenburg J; Niehaus D; Stein DJ Compr Psychiatry; 2001; 42(4):291-300. PubMed ID: 11458303 [TBL] [Abstract][Full Text] [Related]
18. Lymphocyte subsets in major depressive patients. Influence of anxiety and corticoadrenal overdrive. Charles G; Machowski R; Brohee D; Wilmotte J; Kennes B Neuropsychobiology; 1992; 25(2):94-8. PubMed ID: 1625782 [TBL] [Abstract][Full Text] [Related]
19. The dexamethasone suppression test, the Hamilton Depression Rating Scale and the DSM-III depression categories. Maes M; De Ruyter M; Hobin P; Suy E J Affect Disord; 1986; 10(3):207-14. PubMed ID: 2943774 [TBL] [Abstract][Full Text] [Related]
20. Results of the 8 a.m. dexamethasone suppression test constitute a suitable tool for confirming the diagnosis of melancholia. A test unaffected by the variations in the bioavailability of dexamethasone. Maes M; Vandewoude M; Schotte C; Cosyns P Neuropsychobiology; 1989; 22(1):26-32. PubMed ID: 2639285 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]